Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor

Invest New Drugs. 2019 Jun;37(3):591. doi: 10.1007/s10637-019-00757-9.

¹ Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, Japan. itopapa@intmed3.med.kyushu-u.ac.jp.
² Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
³ Department of Surgery, Osaka Police Hospital, Osaka, Japan.
⁴ Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
⁵ Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, Japan.
⁶ Nagoya Daini Red Cross Hospital, Nagoya, Japan.
⁷ Pfizer Japan Inc., Tokyo, Japan.
⁸ Drug Delivery and Formulation Group, Medicinal Chemistry Platform, Ontario Institute for Cancer Research, Toronto, ON, Canada.
⁹ Pfizer Oncology, La Jolla, CA, USA.
¹⁰ Kansai Electric Power Company Hospital, Osaka, Japan.

Abstract

In the original publication of this article, the license subtype should be CC BY and not CC BY-NC.